New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases

被引：42
|
作者：
Mastalerz, Harold
Chang, Ming
Chen, Ping
Dextraze, Pierre
Fink, Brian E.
Gavai, Ashvinikumar
Goyal, Bindu
Han, Wen-Ching
Johnson, Walter
Langley, David
Lee, Francis Y.
Marathe, Punit
Mathur, Arvind
Oppenheimer, Simone
Ruediger, Edward
Tarrant, James
Tokarski, John S.
Vite, Gregory D.
Vyas, Dolatrai M.
Wong, Henry
Wong, Tai W.
Zhang, Hongjian
Zhang, Guifen
机构：
[1] Dept Oncol Chem, Wallingford, CT 06492 USA
[2] Dept Discovery Biol, Wallingford, CT 06492 USA
[3] Dept Pharmaceut Candidate Optimizat, Wallingford, CT 06492 USA
[4] Dept Comp Aided Drug Design, Wallingford, CT 06492 USA
[5] Dept Chem Synth, Wallingford, CT 06492 USA
[6] Bristol Myers Squibb Pharmaceut Inst, Princeton, NJ 08543 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 07期
关键词：
EGFR; HER2; receptor tyrosine kinase inhibitor; pyrrolotriazine;
D O I：
10.1016/j.bmcl.2007.01.002
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Novel C-5 substituted pyrrolotriazines were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition. The lead compound exhibited promising oral efficacy in both EGFR and HER2 driven human tumor xenograft models. It is hypothesized that its C-5 morpholine side chain binds in the ribose phosphate portion of the ATP binding pocket. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2036 / 2042
页数：7
相关论文
共 50 条
  • [41] Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers
    Ghorab, Mostafa M.
    Alsaid, Mansour S.
    Soliman, Aiten M.
    BIOORGANIC CHEMISTRY, 2018, 80 : 611 - 620
  • [42] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.
    Solca, F
    Baum, A
    Guth, B
    Colbatzky, F
    Blech, S
    Amelsberg, A
    Himmelsbach, F
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [43] Inhibitory effects of metachromins L-Q and its related analogs against receptor tyrosine kinases EGFR and HER2
    Takahashi, Yohei
    Kubota, Takaaki
    Yamamoto, Sunao
    Kobayashi, Jun'ichi
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (01) : 117 - 118
  • [44] HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
    Kong, Anthony
    Calleja, Veronique
    Leboucher, Pierre
    Harris, Adrian
    Parker, Peter J.
    Larijani, Banafshe
    PLOS ONE, 2008, 3 (08):
  • [45] Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors
    Milik, Sandra N.
    Abdel-Aziz, Amal Kamal
    Lasheen, Deena S.
    Serya, Rabah A. T.
    Minucci, Saverio
    Abouzid, Khaled A. M.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 : 316 - 336
  • [46] Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2
    Bello, Martiniano
    Saldana-Rivero, Lucia
    Correa-Basurto, Jose
    Garcia, Benjamin
    Armando Sanchez-Espinosa, Victor
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 111 : 569 - 586
  • [47] Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents
    Solca, F.
    Baum, A.
    Himmelsbach, F.
    Amelsberg, A.
    Adolf, G.
    EJC SUPPLEMENTS, 2006, 4 (12): : 172 - 172
  • [48] The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
    Kim, Jin Won
    Kim, Hwang-Phill
    Im, Seock-Ah
    Kang, Soyeong
    Hur, Hyung Seok
    Yoon, Young-Kwang
    Oh, Do-Youn
    Kim, Jee Hyun
    Lee, Dong Soon
    Kim, Tae-You
    Bang, Yung-Jue
    CANCER LETTERS, 2008, 272 (02) : 296 - 306
  • [49] 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors
    Awale, Mahendra
    Mohan, C. Gopi
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2008, 26 (07): : 1169 - 1178
  • [50] Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking
    Elkamhawy, Ahmed
    Farag, Ahmed Karam
    Viswanath, Ambily Nath Indu
    Bedair, Tarek M.
    Leem, Dong Gyu
    Lee, Kyung-Tae
    Pae, Ae Nim
    Roh, Eun Joo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (22) : 5147 - 5154
12345